Gene editing company Metagenomi submits IPO plans

Metagenomi submitted its plans for an initial public offering on Friday night, in what would be one of the only preclinical gene editing biotechs to IPO in the past two years as investors have cooled on the category.

The biotech expects to list on the Nasdaq as Click here to view original post